Nivaan Care Raises $7M for India's Chronic Pain Market

HEALTHCAREBIOTECH
Whalesbook Logo
AuthorRiya Kapoor|Published at:
Nivaan Care Raises $7M for India's Chronic Pain Market
Overview

Nivaan Care has closed a $7 million Series A funding round led by Sorin Investments, with participation from W Health Ventures, Endiya Partners, and Rebright Partners. The capital infusion will drive the expansion of Nivaan's clinic network across Indian cities, bolster its clinical and operational infrastructure, and advance its minimally invasive pain management procedures. This strategic move targets the significant unmet need for specialized chronic pain care in India, where an estimated one in five adults suffers from persistent pain.

### Addressing India's Chronic Pain Gap

The recent $7 million Series A funding round positions Nivaan Care to directly confront the fragmented and often inadequate treatment pathways for chronic pain in India. With nearly one in five adults experiencing persistent pain, the healthcare system frequently offers either basic physiotherapy or invasive surgical options, leaving a substantial segment of patients underserved. Nivaan Care aims to bridge this gap by establishing a dedicated, evidence-based middle layer focused on minimally invasive interventions, offering a less risky alternative to surgery. The company has already demonstrated traction, completing over 40,000 consultations and approximately 5,000 minimally invasive procedures across its existing clinics in Delhi-NCR, Mumbai, Jaipur, and Lucknow.

### Strategic Expansion Fueled by Investor Confidence

Led by Sorin Investments and supported by existing backers W Health Ventures, Endiya Partners, and Rebright Partners, this funding round signifies strong conviction in Nivaan Care's scalable business model. Investors highlighted the inherent difficulties in scaling specialized pain management within traditional hospital frameworks, positioning Nivaan's comprehensive, full-stack solution as a distinct advantage. Mandar Dandekar, a partner at Sorin Investments, noted the significant addressable patient base and the limited presence of organized players as key factors favoring Nivaan's growth trajectory towards becoming India's leading integrated pain management platform.

The capital injection is earmarked for strategic expansion into new markets, including Bengaluru, and bolstering operational capabilities in select satellite cities. The founding team brings substantial experience in scaling healthcare ventures, with co-founder and CEO Nivesh Khandelwal having previously managed growth at Ridge IVF, and COO Vishwas Singh holding leadership roles at companies like Tata 1mg and Shuttl. This seasoned leadership, combined with a focus on advanced regenerative medicine and a multidisciplinary approach involving pain physicians and physiotherapists, underpins the company's strategy for delivering superior patient outcomes.

### Market Opportunity and Future Trajectory

The interventional pain management sector in India is experiencing growth, driven by an increasing prevalence of chronic conditions and an aging demographic seeking less invasive treatment options. Nivaan Care operates in a segment characterized by high demand and a supply gap, particularly for specialized, organized care providers. The company's focus on minimally invasive procedures aligns with global trends favoring outpatient care and reduced recovery times. While specific financial metrics like P/E ratios and market capitalization are not publicly available for Nivaan Care as a private entity, investor confidence, evidenced by this Series A round, points to a strong belief in the company's ability to capture a significant share of this expanding market.

Disclaimer:This content is for educational and informational purposes only and does not constitute investment, financial, or trading advice, nor a recommendation to buy or sell any securities. Readers should consult a SEBI-registered advisor before making investment decisions, as markets involve risk and past performance does not guarantee future results. The publisher and authors accept no liability for any losses. Some content may be AI-generated and may contain errors; accuracy and completeness are not guaranteed. Views expressed do not reflect the publication’s editorial stance.